Printer Friendly

Actavis gets FDA approval to market Zolpidem Tartrate Extended-Release Tablets.

M2 PHARMA-October 19, 2010-Actavis gets FDA approval to market Zolpidem Tartrate Extended-Release Tablets(C)2010 M2 COMMUNICATIONS

19 October 2010 - Iceland-based generic pharmaceuticals company Actavis Group announced yesterday it has received approval from the US Food and Drug Administration (FDA) to market Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV.

Distribution of the product has commenced.

As the first company to file an ANDA that contained a paragraph IV certification for Ambien CR 6.25mg, Actavis has been awarded 180-day exclusivity to market this product.

Zolpidem Tartrate Extended-Release Tablets 6.25mg, the generic equivalent of Ambien CR 6.25mg by sanofi-sventis, had US sales of approximately USD129m (EUR92.7m) for the 12 months ending 30 June 2010, according to IMS Health.

(USD1 = EUR0.719)

((Comments on this story may be sent to

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:4EXIC
Date:Oct 19, 2010
Previous Article:FDA approves BARACLUDE as treatment of CHB patients with decompensated liver disease.
Next Article:Hanger signs definitive merger agreement to acquire ACP.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters